EUVIMEDEUVIMED entdecken
Multizentrische StudieRandomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Clinical evaluation of MyoCare in Europe (CEME) for myopia management: One‐year results

Cristina Alvarez-Peregrina iD, Miguel Angel Sanchez-Tena iD, Cesar Villa-Collar iD, Clara Martinez-Perez iD, Beatriz de Corcuera-Terrero, Nicole Liu iD, Wayne Li, Padmaja Sankaridurg iD, Arne Ohlendorf iD, Clinical Evaluation of MyoCare in Europe – the CEME Study Group

Ophthalmic and Physiological Optics · 2025-06 · 45 (4) · 1025-1035

DOI: 10.1111/opo.13517 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Ophthalmic and Physiological Optics, online erschienen am 29.04.2025. Verfasst von Cristina Alvarez-Peregrina und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Optometry and Vision, Faculty of Optics and Optometry, Universidad Complutense de Madrid, Madrid, Spain. Hauptthemen laut MEDLINE: Eyeglasses, Myopia, Refraction, Ocular, Visual Acuity. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Zeiss Vision Care.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

To evaluate the efficacy of CARE spectacle lenses in slowing myopia progression among European children.

Methods

In a 2‐year randomised, parallel‐group, double‐masked, multicentre clinical trial, 234 European children aged 6–13 years were enrolled. All participants were myopic, with a cycloplegic spherical equivalent refractive error (SE) between −0.75 D and −5.00 D, astigmatism ≤1.50 D, anisometropia ≤1.00 D and myopia progression of at least 0.50 D in the previous year. The treatment group received MyoCare spectacle lenses with cylinder annular refractive elements (CARE), the control group single‐vision lenses (SVL). Axial length (AL) and SE were measured at baseline, 6 and 12 months. Wearability questionnaires were administered at 1 week and 3 months. Central and peripheral visual acuity (VA) was recorded at dispensing and after 3 months. Generalised linear models estimated changes in SE and AL, adjusting for lens type, age and baseline measurements.

Results

After 12 months, children wearing CARE lenses showed less myopia progression, with a difference in SE and AL progression (compared to SVL) of −0.21 D (CI: 0.10 to 0.32 D) and 0.14 mm (CI: −0.17 to −0.10 mm), respectively. Central VA did not decrease with CARE lenses. Peripheral VA decreased by 0.10 and 0.09 logMAR in the nasal and temporal zones, respectively. Analysis of fast progressors indicated that 39.7% of SVL wearing eyes progressed by ≤−0.50 D/year compared to 21.1% with CARE ( p < 0.01). For AL, 56.0% of SVL children had an elongation ≥0.20 mm compared to 21.3% with CARE ( p < 0.01).

Conclusions

In European children, myopia progression was significantly slower with CARE lenses compared with SVL after 1 year of lens wear. Further monitoring will provide a comprehensive evaluation of long‐term efficacy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

EyeglassesMyopiaRefraction, OcularVisual AcuityAdolescentChildFemaleHumansMaleDisease ProgressionDouble-Blind MethodEuropeFollow-Up StudiesTime FactorsTreatment OutcomeProspective Studies

Stichwörter der Autor:innen

Europechildrenmyopia controlophthalmic lens

Autor:innen und Institutionen

  • Department of Optometry and Vision, Faculty of Optics and Optometry, Universidad Complutense de Madrid, Madrid, Spain.
  • ISEC LISBOA-Instituto Superior de Educação e Ciências, Lisbon, Portugal.
  • Faculty of Biomedical and Health Sciences, Universidad Europea de Madrid, Madrid, Spain.
  • School of Optometry and Vision Science, University of New South Wales, Sydney, Australia.
  • ZEISS Vision Care, Carl Zeiss Vision International GmbH, Aalen, BW, Germany.
  • ZEISS Vision Care, Carl Zeiss Vision (Guangzhou) Ltd., Guangzhou, China.

ORCID-Profile: Cristina Alvarez-Peregrina, Miguel Angel Sanchez-Tena, Cesar Villa-Collar, Clara Martinez-Perez, Nicole Liu, Padmaja Sankaridurg, Arne Ohlendorf

Förderung

  • Zeiss Vision Care

Zitieren

APA

Alvarez-Peregrina, C., Sanchez-Tena, M. A., Villa-Collar, C., Martinez-Perez, C., de Corcuera-Terrero, B., Liu, N., Li, W., Sankaridurg, P., Ohlendorf, A., & Clinical Evaluation of MyoCare in Europe – the CEME Study Group (2025). Clinical evaluation of MyoCare in Europe (CEME) for myopia management: One‐year results. Ophthalmic and Physiological Optics, 45(4), 1025-1035. https://doi.org/10.1111/opo.13517

Vancouver

Alvarez-Peregrina C, Sanchez-Tena MA, Villa-Collar C, Martinez-Perez C, de Corcuera-Terrero B, Liu N, et al. Clinical evaluation of MyoCare in Europe (CEME) for myopia management: One‐year results. Ophthalmic and Physiological Optics. 2025;45(4):1025-1035. doi:10.1111/opo.13517

BibTeX
@article{AlvarezPeregrina2025,
  author = {Alvarez-Peregrina, Cristina and Sanchez-Tena, Miguel Angel and Villa-Collar, Cesar and Martinez-Perez, Clara and de Corcuera-Terrero, Beatriz and Liu, Nicole and Li, Wayne and Sankaridurg, Padmaja and Ohlendorf, Arne and Clinical Evaluation of MyoCare in Europe – the CEME Study Group, Clinical Evaluation of MyoCare in Europe – the CEME Study Group},
  title = {Clinical evaluation of MyoCare in Europe (CEME) for myopia management: One‐year results},
  journal = {Ophthalmic and Physiological Optics},
  year = {2025},
  volume = {45},
  number = {4},
  pages = {1025--1035},
  doi = {10.1111/opo.13517}
}
Kostenlos starten →